BMO Capital Sticks to Their Buy Rating for Merck & Company

By Jason Carr

In a report released today, Alex Arfaei from BMO Capital maintained a Buy rating on Merck & Company (NYSE: MRK), with a price target of $65. The company’s shares closed on Friday at $57.17.

According to TipRanks.com, Arfaei is a 4-star analyst with an average return of 4.3% and a 62.7% success rate. Arfaei covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Bristol Myers, and AstraZeneca.

Currently, the analyst consensus on Merck & Company is Moderate Buy and the average price target is $62.33, representing a 9.0% upside.

In a report issued on April 5, Barclays also upgraded the stock to Buy with a $64 price target.

Based on Merck & Company’s latest earnings report for the quarter ending December 31, the company posted quarterly revenue of $10.43 billion and GAAP net loss of $1.05 billion. In comparison, last year the company earned revenue of $9.34 billion and had a net profit of $1.55 billion.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.